Trasylol Label Should Get Warning, But Not Study Details Advisory Cmte. Says
Executive Summary
Following a Sept. 12 advisory committee meeting evaluating safety signals for Bayer's Trasylol (aprotinin), FDA faces the question of how to re-label a drug with uncertain but serious risks
You may also be interested in...
Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market
Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market
Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
FDA and Bayer will begin discussions of post-marketing studies for the firm's Trasylol (aprotinin) due to suggestive but inconclusive observational data linking the drug to renal events and death